Brief: Cyclo Therapeutics Announces Last Patient Last Visit In Phase 1/2 Trial Evaluating Trappsol Cyclo For The Treatment Of Niemann-Pick Disease Type C
04/03/2021 14:31
March 4 (Reuters) - Cyclo Therapeutics Inc CYTH.O :
* CYCLO THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN
PHASE
1/2 TRIAL EVALUATING TRAPPSOL® CYCLO™ FOR THE TREATMENT OF
NIEMANN-PICK DISEASE TYPE C
* CYCLO THERAPEUTICS INC - PIVOTAL PHASE 3 STUDY EVALUATING
TRAPPSOL(®) CYCLO™ FOR TREATMENT OF NPC EXPECTED TO COMMENCE
ENROLLMENT IN Q2 2021
* CYCLO THERAPEUTICS INC - EXPECTS TO REPORT TOPLINE DATA
FOR
PHASE 1/2 STUDY IN MARCH 2021
Source text for Eikon: ID:nBw8XMb3sa
Further company coverage: CYTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug